In NSCLC, RET rearrangements occur at a frequency of approximately 1–2% in unselected patient populations and are generally non-overlapping with alterations in other oncogenic drivers, such as EGFR, ALK, and ROS1 [46,47,48,54,55]. This evidence concerns the gene RET and non-small cell lung carcinoma.